Mike Hollan

AI provides opportunities to bring people together—not replace them.

The industry is facing an uncertain regulatory landscape in the coming year.

This acquisition will bring Aliada’s Alzheimer’s treatment under AbbVie’s pipeline.

The report details the experiences of Hispanic, Black, and Asian patients.

Both firms were heavily focused on pharma and healthcare marketing during the previous year.

The actress is participating in the campaign for its third year.

The videos are designed to help bring people together during the holidays.

In this first part of this roundtable discussion, experts discuss the current perception of AI and how this is impacting adoption.

The report gives high rankings to brands from Pfizer and AstraZeneca.

EVERSANA’s chief digital officer discusses the current relationship between pharma and AI.

The musician launched the Get Low #2 campaign.

The non-profit’s new CEO discusses her role and how she plans to steer the organization towards the future.

The devices are being provided based on a variety of health-based features that they provide.

AIX exchanged key assets in exchange for ownership shares.

The two companies will work to develop treatments for SBMA.

CelloType produces more accurate results when analyzing high content tissue images.

The educational platform is targeted at HCPs and their staff.

The actor is part of a campaign for early colon cancer screening.

The results say that the industry still lacks talent and skills in this area.

The campaign also includes partnerships with other celebrities, including Lance Bass and Retta.

Dorman previously served as head of Gilead Sciences’ U.S. Oncology Unit.

The drug, developed by UCB, is approved to treat adults with the inflammatory skin disease.

Syndax describes the drug as the first of its kind.

The news is part of the organization’s goal of demonstrating a commitment to women’s health.

The contest focused on telling the stories of how migraines impacted patients’ careers.

Etira’s CEO discusses recent developments in R&D and with the company’s leadership.

A look at one biotech’s mission to map the immune system using artificial intelligence—and how its growth as a Big Pharma partner could help unlock the potential of next-generation cancer treatments.

Ann Beliën, PhD, founder and CEO of Rejuvenate Biomed, discusses how AI is being used to find new ways to treat age-related conditions.

The Jazz Pharmaceutical president and COO discusses her approach to the role and how it plays into the company’s overall goals.

The survey is part of an initiative from GSK to improve these gaps.